The abstract is read at the publisher; the summary is JClub's.
In a phase 3 trial in Chinese women aged 18–45, the E. coli-produced 9vHPV vaccine showed non-inferior neutralizing antibody responses versus 2vHPV, with GMC ratios of 0·60 (HPV 16) and 0·64 (HPV 18) at month 7.
- Why it matters: High-valency HPV vaccination can broaden protection, but evidence is needed on efficacy, safety, and immunogenicity for a nine-valent, E. coli-produced product in real-world trial settings.
- What they did: In five local health centres in Jiangsu and Sichuan, 9327 eligible women were randomized 1:1 to three doses at day 0, month 1, and month 6, and coprimary endpoints assessed month-7 neutralizing antibodies and 12-month persistent infection.
- The result: Efficacy against 12-month persistent infection linked to HPV 31, 33, 45, 52, and 58 was 98·2% (95% CI 89·6–100), with adverse reactions reported in 52·1% versus 42·2% and serious adverse events at similar rates.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.